Clinical Trial

A Study of Safety and Efficiency of AND017 in Patients With β-thalassemia

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a phase II, randomized, double-blinded, placebo-controlled study to treat patients with transfusion-dependent and non-transfusion dependent β -thalassemia with AND017 and optimal supportive care, including blood transfusion and iron removal, based on the clinician's judgment and practice.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-03-04; most recent amendment 2026-02-25.
Status change: Not Yet Recruiting → Recruiting 2024-06-26
Trial Details
NCT Number NCT06302491
Lead Sponsor Kind Pharmaceuticals LLC
Conditions β -Thalassemia
Enrollment 64 participants
Start Date 2024-05-27
Primary Completion 2026-12 (estimated)
Study Completion 2027-07 (estimated)
Updated on ClinicalTrials.gov 2026-02-27